Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

Journal of Neural Transmission

Volumn 104, Issue 2-3, 1997, Pages 209-228

  Carvey, P M ^a   Pieri, S ^a   Ling, Z D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bromocriptine; Levodopa; Mesencephalic cultures; Neuroprotection; Oxidant stress; Pergolide; Pramipexole; Toxicity; Trophic factor

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; CULTURE MEDIUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG POTENCY; FETUS; MESENCEPHALON; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STEREOISOMERISM; TISSUE CULTURE;

EID: 0030897345     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273182     Document Type: Article

References (49)

1. Adams JD, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10: 161-169
2. Althaus JS, Fici GJ, VonVoigtlander PF (1996) The dopamine agonist pramipexole blocks the oxidative toxicity of L-DOPA in culture. Soc Neurosci Abstr 22: 219
3. Baczynskyj L, Althaus JS, VonVoigtlander PF (1996) Electrochemical oxidation of pramipexole. 44th ASMS Conference on Mass Spectrometry and Allied Topics
4. Blunt SB, Jenner P, Marsden CD (1991) The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography. Neuroscience 43: 95-110
5. Blunt SB, Jenner P, Marsden CD (1993) Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8: 129-133
6. Brundin P, Isacson O, Bjorklund A (1985) Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res 331: 251-259
7. Calne DB, Zigmond MJ (1991) Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Arch Neurol 48: 361-363
8. Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF (1995) Rat brain binding sites for pramipexole, a clinically useful DS-preferring dopamine agonist. Neurosci Lett 196: 97-100
9. Carter AJ, Muller RE (1991) Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 200: 65-72
10. Carvey PM, Ptak LR, Lo ES, Lin DH, Buhrfiend CM, Goetz CG, Klawans HL (1991) Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures. Exp Neurol 114: 28-34
11. Carvey PM, Ptak LR, Lin D, Lo ES, Buhrfiend CM, Drucker GE, Fields JZ (1993) Alterations in striatal neurotrophic activity induced by dopaminergic drugs. Pharmacol Biochem Behav 46: 195-204
12. Dal Toso R, Giorgi O, Soranzo C, Kirschner G, Ferrari G, Favaron M, Benvegnu D, Presti D, Vicini S, Toffano G (1988) Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF). J Neurosci 8: 733-745
13. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
14. Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA (1992) Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 13: 339-351
15. Fornstedt B, Brun A, Rosengren E, Carlsson A (1989b) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [PD Sect] 1: 279-295
16. Goldstein M, Lew JY, Sauter A, Lieberman A (1980a) The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites. Adv Biochem Psychopharmacol 23: 75-82
17. Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH (1980b) Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 77: 3725-3728
18. Graham DG, Tiffany SM, Bell WR, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644-653
19. Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res (in press)
20. Hefti F, Melamed E, Bhawan J, Wurtman RJ (1981) Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 31: 1194-1195
21. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-34
22. Hubble JP, Koller WC, Cutler N, Friedman J, Goetz CG, Ranhosky A, Korts D, Elvin A (1995) Pramipexole, a highly selective dopamine agonist in patients with early Parkinson's disease: an ascending-dose trial. Clin Neuropharmacol 18: 338-347
23. Jenner P (1995) The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45: S6-12
24. Kontur PJ, Marek K, Roth R, Redmond DE (1993) Effects of L-dopa and dopamine receptor agonists on cultured rat mesencephalic dopamine neurons. Neurology 43: A153
25. Ling ZD, Pieri S, Carvey PM (1996) Comparison of the neurotoxicity of dopa stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 4: 360-365
26. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA (1994) Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol 17: 370-379
27. Mena MA, Pardo B, Casarejos MJ, Fahn S, deYebenes JG (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7: 23-31
28. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26: 428-435
29. Mierau J (1995) Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol 18 [Suppl 1]: S195-S206
30. Mierau J, Bechtel WD (1988) SND 919 inhibits dopamine release in vivo and in vitro (abstract). Psychopharmacology 96: 338
31. Mierau J, Schingnitz G (1992) Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215: 161-170
32. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290: 29-36
33. Mons N, Tison F, Geffard M (1989) Identification of L-dopa-dopamine and L-dopa cell bodies in the rat mesencephalic dopaminergic cell systems. Synapse 4: 99-105
34. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32 [Suppl]: S2-9
35. Perry TL, Yong VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM (1984) Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 43: 990-993
36. Piercey MF, Camacho-Ochoa M, Smith MW (1995) Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 18 [Suppl 1]: S34-S42
37. Piercey MF, Hoffman WE, Smith MW, Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other agonists. Eur J Pharmacol 312: 35-44
38. Prochiantz A, Daguet MC, Di Porzio U, Herbet A, Glowinski J (1983) In vitro studies on central dopaminergic neurons' development. Prog Brain Res 58: 365-368
39. Robertson GS, Tham CS, Wilson C, Jakubovic A, Fibiger HC (1993) In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 264: 1344-1351
40. Sahakian BJ, Carlson KR, DeGirolami U, Bhawan J (1980) Functional and structural consequences of long-term dietary L-dopa treatment in mice. Commun Psychopharmacol 4: 169-176
41. Salah RS, Kuhn DM, Galloway MP (1989) Dopamine autoreceptors modulate the phosphorylation of tyrosine hydroxylase in rat striatal slices. J Neurochem 52: 1517-1522
42. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM (1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342: 321-334
43. Spina MB, Cohen G (1988) Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione [published erratum appears in J Pharmacol Exp Ther (1989) 248(1): 478]. J Pharmacol Exp Ther 247: 502-507
44. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR (1990) Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 110: 201-208
45. Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, Hoffer B, Humpel C (1993) Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124: 401-412
46. Tison F, Normand E, Jaber M, Aubert I, Bloch B (1991) Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 127: 203-206
47. Tomozawa Y, Appel SH (1986) Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro. Brain Res 399: 111-124
48. Youdim MB, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease [published erratum appears in Mov Disord (1993) 8(2): 255]. Mov Disord 8: 1-12
49. Yu SJ, Lo ES, Cochran EJ, Lin DH, Faselis CJ, Klawans HL, Carvey PM (1994) Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol 126:15-24